Table 1.
Baseline characteristicsa.
| Characteristic | Olaparib alone (n = 23) | Olaparib plus durvalumab (n = 22) |
|---|---|---|
| Median (range) age, years | 48 (35–77) | 51.5 (25–72) |
| Age, years | ||
| ≤65 | 19 (83) | 21 (95) |
| >65 | 4 (17) | 1 (5) |
| Race | ||
| Asian | 16 (70) | 18 (82) |
| White | 5 (22) | 4 (18) |
| Other/missing | 2 (9) | 0 |
| ECOG performance status | ||
| 0 | 16 (70) | 13 (59) |
| 1 | 7 (30) | 8 (36) |
| 2 | 0 | 1 (5) |
| Most recent platinum regimen | ||
| 1st line | 18 (78) | 19 (86) |
| 2nd line | 5 (22) | 3 (14) |
| Median (range) duration of prior platinum, months | 2.9 (1.4–5.9) | 2.7 (1.4–22.3) |
| Best response to prior platinum | ||
| CR/PR | 14 (61) | 13 (59) |
| SD | 9 (39) | 9 (41) |
| Germline BRCA status | ||
| Deleterious mutation | 1 (4)b | 7 (32)c |
| No mutation detected/variant of unknown significance | 13 (57) | 6 (27) |
| Not testedd | 9 (39) | 9 (41) |
| Tumor cells positive for estrogen receptor | ||
| <1% | 21 (91) | 21 (95) |
| ≥1%–≤10% | 2 (9) | 0 |
| Missing | 0 | 1 (5) |
| Tumor cells positive for progesterone receptor | ||
| <1% | 23 (100) | 0 |
| ≥1%–≤10% | 0 | 1 (5) |
| DFI from initial diagnosis to advanced/metastatic TNBC | ||
| De novo | 7 (30) | 4 (18) |
| ≤1 year | 3 (13) | 2 (9) |
| >1 year | 13 (57) | 16 (73) |
| Median (range) interval between metastatic diagnosis and randomization, months | 5.3 (2.7–61.2) | 4.9 (2.5–14.6) |
Note: Data are n (%) unless otherwise specified.
Abbreviations: CR/PR, complete response/partial response; DFI, disease-free interval; ECOG, Eastern Cooperative Oncology Group; SD, stable disease; TNBC, triple-negative breast cancer.
aPlease see the full table in the Supplementary Table S2.
b BRCA2.
cAll BRCA1.
d BRCA testing is less readily available at Asian sites.